MENU
+Compare
HRTS
ETF ticker: NASDAQ
AS OF
Aug 13, 04:25 PM (EDT)
Price
$28.46
Change
+$0.46 (+1.64%)
Net Assets
46.6M

HRTS stock forecast, quote, news & analysis

The investment seeks to provide long-term growth of capital... Show more

Category: #Health
HRTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for HRTS with price predictions
Aug 12, 2025

HRTS sees its Stochastic Oscillator climbs out of oversold territory

On August 12, 2025, the Stochastic Oscillator for HRTS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 20 instances where the indicator left the oversold zone. In of the 20 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HRTS advanced for three days, in of 108 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 05, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HRTS as a result. In of 23 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for HRTS turned negative on July 29, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 18 similar instances when the indicator turned negative. In of the 18 cases the stock turned lower in the days that followed. This puts the odds of success at .

HRTS moved below its 50-day moving average on July 30, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for HRTS crossed bearishly below the 50-day moving average on August 07, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 5 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRTS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HRTS broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for HRTS entered a downward trend on August 12, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), ABBVIE (NYSE:ABBV), Unitedhealth Group (NYSE:UNH), AstraZeneca PLC (NASDAQ:AZN), Abbott Laboratories (NYSE:ABT), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Boston Scientific Corp (NYSE:BSX), Gilead Sciences (NASDAQ:GILD), Medtronic plc (NYSE:MDT).

Industry description

The investment seeks to provide long-term growth of capital. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund generally is expected to consist of more than 15 companies but not more than 100 companies. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Heart & Health ETF ETF is 81.09B. The market cap for tickers in the group ranges from 3.51M to 592.1B. LLY holds the highest valuation in this group at 592.1B. The lowest valued company is NOVN at 3.51M.

High and low price notable news

The average weekly price growth across all stocks in the Tema Heart & Health ETF ETF was 57%. For the same ETF, the average monthly price growth was 44%, and the average quarterly price growth was 69%. MIRM experienced the highest price growth at 25%, while LLY experienced the biggest fall at -17%.

Volume

The average weekly volume growth across all stocks in the Tema Heart & Health ETF ETF was 5%. For the same stocks of the ETF, the average monthly volume growth was 7% and the average quarterly volume growth was 6%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 73
Price Growth Rating: 55
SMR Rating: 73
Profit Risk Rating: 70
Seasonality Score: -25 (-100 ... +100)
View a ticker or compare two or three
HRTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
United Satets
Phone
N/A
Web
www.tema.co